Join Growin Stock Community!

Sellas life sciences group, inc.SLS.US Overview

US StockHealthcare
(No presentation for SLS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SLS AI Insights

SLS Overall Performance

SLS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SLS Recent Performance

-0.31%

Sellas life sciences group, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SLS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SLS Key Information

SLS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SLS Profile

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Price of SLS

SLS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SLS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.18
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
26.90
PB Ratio
18.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.18
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
26.90
PB Ratio
18.34
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is SLS's latest earnings report released?

    The most recent financial report for Sellas life sciences group, inc. (SLS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SLS's short-term business performance and financial health. For the latest updates on SLS's earnings releases, visit this page regularly.

  • How much cash does SLS have?

    At the end of the period, Sellas life sciences group, inc. (SLS) held Total Cash and Cash Equivalents of 44.42M, accounting for 0.86 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SLS's EPS continuing to grow?

    According to the past four quarterly reports, Sellas life sciences group, inc. (SLS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SLS?

    Sellas life sciences group, inc. (SLS)'s Free Cash Flow (FCF) for the period is -7.07M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 9.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.